乙型肝炎病毒相关性肝细胞癌抗病毒治疗现状  

The Current Situation of Antiviral Therapy for Hepatitis B Virus-related Hepatocellular Carcinoma

作　　者：袁宝红[1] 钟鉴宏[1] 袁卫平[1] 

机构地区：[1]广西医科大学附属肿瘤医院肝胆外科,南宁530021

出　　处：《医学综述》2015年第14期2552-2555,共4页Medical Recapitulate

摘　　要：乙型肝炎病毒(HBV)感染是我国肝细胞癌(HCC)的主要病因,高病毒载量是影响HCC发生、发展及预后的重要因素。针对HCC的各种治疗均有激活HBV的可能性,治疗的同时联合抗病毒治疗有利于抑制病毒的再激活,促进肝功能的恢复和减少并发症的发生,在针对HCC的治疗后持续的抗病毒治疗有利于抑制病毒复制,减少肿瘤复发与转移,延长患者生存时间并改善生活质量。抗病毒治疗是乙型肝炎相关性肝细胞癌的最基本病因治疗,在HCC的治疗中具有重要意义。Hepatitis B virus（HBV） is the main cause of hepatocellular carcinoma（HCC） in China.High HBV load is an important factor affecting the occurrence,development and prognosis of HCC.Since these treat-ments aiming at hepatic tumor have the potential to reactivate HBV , combination of antiviral therapy at the same time is conducive to restrain HBV reactivation , promote liver function recovery and reduce complica-tion .Persistent antiviral therapy after finishing the treatment aiming at HCC is conducive to restrain HBV rep-lication,reduce HCC relapse and transfer,prolong survival time and improve the quality of life.As the most fundamental treatment for HBV related HCC, antiviral therapy has great significance for the treatments of HCC.

关 键 词：肝细胞癌 乙型肝炎病毒 抗病毒治疗 

分 类 号：R735.7[医药卫生—肿瘤] R730.55[医药卫生—临床医学]